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Assessment of Electronic Alert to Reduce Overuse of Granulocyte Colony-Stimulating Factor in Patients Hospitalized for Febrile Neutropenia
Prophylactic granulocyte colony-stimulating factors (G-CSFs) reduce the risk of febrile neutropenia (FN). 1 Owing to the efficacy of prophylactic G-CSF, multiple studies have evaluated the therapeutic use of G-CSF during FN; however, no difference in overall mortality or infection-related mortality was observed. 2 American Society of Clinical Oncology (ASCO) guidelines state that "GCSFs should not be used for the treatment of FN. However, GCSFs can be considered in patients at high-risk for complications." 1(p3204) Despite these guidelines, up to 62% of patients with FN receive G-CSF. 3 Our objective was to evaluate the efficacy of an alert in the electronic health record (EHR) in reducing the therapeutic use of G-CSF.
Methods | This study was conducted from February 12, 2014, to April 12, 2016, at an academic multisite hospital where all orders are entered electronically. Beginning March 12, 2015, an EHR alert was triggered by the entry of an order for filgrastim or tbo-filgrastim. Clinicians were prompted to select an indication from a dropdown menu. If FN was selected, ASCO guidelines were displayed, and clinicians were required to select the indication. 1 We compared the use of G-CSF the year prior to with the use of G-CSF the year after the alert was implemented. The study was approved by the Columbia University Medical Center and Weill Cornell Medical Center Institutional Review Boards, who waived patient consent, as the data were deidentified. Patients were eligible if they had cancer and were hospitalized with FN. Covariates included age, sex, cancer type, and insurance. Patients were categorized as high risk if they were older than 65 years of age or had sepsis, pneumonia, or an invasive fungal infection. All analyses were conducted with SAS, version 9.4 software (SAS Institute Inc). P < .05 (2-sided) was considered significant. (Table) . There was no change in the use of G-CSF use before and after the alert (60 of 544 admissions [11.0%] vs 46 of 336 admissions [13.7%]; P = .61). Among the low-risk admissions, the use of G-CSF increased from 27 of 121 (22.3%) prior to the EHR alert to 40 of 116 (34.5%) after (P = .04) (Figure) . (Table) .
Results
Discussion | We found that approximately one-third of patients hospitalized with FN received G-CSF, and the level of use did not decrease after the implementation of an EHR alert.
Letters
Although all patients were hospitalized with FN, only 40.7% of clinicians selected FN as the indication for use of G-CSF. In addition, 42 of 108 clinicians (38.9%) selected an indication that was not applicable to the patient's clinical status. This pattern of response suggests that clinicians may have been trying to circumvent the EHR alert, which may explain the lack of efficacy.
There are several explanations for why our intervention was not effective. Clinicians may not agree with the ASCO guidelines. 1 Prior studies suggest that EHR alerts are ignored up to 96% of the time. 4 Our study differs in that our intent was to reduce the overuse of G-CSF rather than improve safety. In our study, the fact that clinicians frequently selected nonapplicable indications for the use of G-CSF is consistent with alert fatigue. An alternative approach is the use of an automated order entry in specific clinical situations. 5 Our work has several limitations. This was a 1-year study conducted across 2 campuses. Thus, our findings can be skewed by a few clinicians. The sites were urban academic centers, which may limit the generalizability. This was not a randomized clinical trial, and our results may be confounded by changes in personnel, practice patterns, and the patient population over time. Finally, ASCO's definition of a high-risk patient is subjective, which may have led to misclassification. 
Breast Cancer With a Poor Prognosis Diagnosed After Screening Mammography With Negative Results
Approximately 15% of breast cancers are diagnosed after the patient undergoes screening mammography with negative results and before the next recommended screening examination. 1 These interval cancers (cases of cancer diagnosed during the interval between examinations) include both cancers that were present during screening mammography but were missed on examination and rapidly growing cancers that present symptomatically and tend to have a poorer prognosis than cancers detected during screening. [1] [2] [3] Identifying women who are at high risk of breast Among all patients, use of G-CSF did not change after the implementation of an alert in the electronic health record. ICU indicates intensive care unit.
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